Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FRRH9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $33,168.26 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Stelara 90 mg/mL syringes. This firm fixed-price delivery order, issued on December 18, 2025, with an ultimate completion date of January 12, 2026, was awarded without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee based on its established performance as a critical supplier within the federal pharmaceutical supply chain and its registration in the System for Award Management since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. Through this prime vendor program, DMS Pharmaceutical Group serves as a critical supplier for Department of Defense healthcare operations, authorized to provide a comprehensive range of pharmaceuticals including branded and generic prescription drugs, biologics, vaccines, and specialty medical consumables to support military medical requirements globally.
Quick answers
Who was awarded contract SPE2DR26FRRH9?
SPE2DR26FRRH9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FRRH9 worth?
The government has obligated $33,168 on SPE2DR26FRRH9.
Is contract SPE2DR26FRRH9 an order under another contract?
Yes. SPE2DR26FRRH9 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRH9 competed?
The extent of competition for SPE2DR26FRRH9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award